Patients receiving CTLA-4 inhibitors have a higher risk of developing hypophysitis, while those receiving PD-1/PD-L1 inhibitors possess a higher risk of primary thyroid dysfunction and, rarely, type 1 diabetes mellitus, central diabetic insipidus, and hypoparathyroidism [62]. The gene discussed is CTLA4; the disease is diabetes mellitus.